ImmunityBio Stock Surges on EU Approval for Bladder Cancer Treatment

Market Momentum and Global Expansion

The stock climbed 32% to $7.94 following the announcement, extending a rally that has seen the company’s valuation more than double over the past 12 months. This European expansion marks a significant milestone for the biotech firm, which secured its first U.S. Food and Drug Administration approval for the drug less than two years ago.

The regulatory green light followed clinical trials where patients treated with the Anktiva combination demonstrated a 71% complete response rate. With this latest authorization, Anktiva is now approved in 33 countries across four major regulatory jurisdictions, significantly widening the global market for the immunotherapy.

Under the terms of the conditional authorization, ImmunityBio must provide ongoing data to the European Medicines Agency. The company confirmed it will continue to monitor trial participants to submit comprehensive long-term safety and efficacy results as part of the post-market surveillance process.